1-9 of 9
Richy Agajanian
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Acalabrutinib Plus Rituximab with or without Lenalidomide in Patients with Follicular Lymphoma: A Multipart, Open-Label, Phase 1b Trial

Paolo Strati, Beth Christian, Peter Martin, Becky Champion, Morton Coleman, Richy Agajanian, Sonali M. Smith, Parameswaran Venugopal, Izidore S. Lossos, Robert Kridel, Roser Calvo, Kara Higgins, Deborah M. Stephens
Journal: Blood
Blood (2022) 140 (Supplement 1): 3606–3608.
https://doi.org/10.1182/blood-2022-159158
Published: 2022
Journal Articles

Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study

Kerry A. Rogers, MD, Michael A. Boxer, MD, Michael Y. Choi, MD, Richy Agajanian, MD, Donald M. Arnold, MD, Catherine M. Broome, MD, Joshua J. Field, MD, Irina Murakhovskaya, MD, Donna Chow, Robert P. Numerof, PhD, Hanzhe Zheng, PhD, Sandy Tong, MD, David J. Kuter
Journal: Blood
Blood (2019) 134 (Supplement_1): 3518.
https://doi.org/10.1182/blood-2019-126509
Published: 2019
Journal Articles

Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Multicenter, Open-Label Extension Period of the Soar Phase 2 Study

David J. Kuter, MD DPhil, Richy Agajanian, MD, Donald M. Arnold, MD MSc, FRCPC, Michael Boxer, MD, Catherine Broome, MD, Joshua J. Field, MD, Irina Murakhovskaya, MD, Kerry A. Rogers, MD, Ann M Lowe, MD, Sandra Tong, MD, Hany Zayed, PhD, Anne-Marie Duliege, MD MS
Journal: Blood
Blood (2018) 132 (Supplement 1): 3612.
https://doi.org/10.1182/blood-2018-99-110483
Published: 2018
Journal Articles

Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed

David Siegel, MD PhD, Gary J. Schiller, MD, Kevin W Song, MD, Richy Agajanian, Ketih Stockerl-Goldstein, Hakan Kaya, Michael Sebag, MD PhD, Christy Samaras, Ehsan Malek, MD, Giampaolo Talamo, Christopher S. Seet, Jorge Mouro, MS, Faiza Zafar, MPAS, Weiyuan Chung, Shankar Srinivasan, PhD, Max Qian, Amit Agarwal, MD PhD, Anjan Thakurta, PhD, Nizar J. Bahlis, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1812.
https://doi.org/10.1182/blood.V130.Suppl_1.1812.1812
Published: 2017
Journal Articles

A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)

Ralph V. Boccia, Alberto Bessudo, Richy Agajanian, Paul Conkling, Wael Harb, Hui Yang, Dawn Pinchasik, Amy S. Kimball, James R. Berenson, MD
Journal: Blood
Blood (2016) 128 (22): 3325.
https://doi.org/10.1182/blood.V128.22.3325.3325
Published: 2016
Journal Articles

Pomalidomide + Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Study Investigating Efficacy and Safety

David S. Siegel, MD PhD, Gary J. Schiller, MD, Kevin W. Song, MD, Richy Agajanian, Keith Stockerl-Goldstein, Hakan Kaya, Michael Sebag, MD PhD, Fred J. Reu, Ehsan Malek, MD, Jorge L Mouro, Weiyuan Chung, Shankar Srinivasan, PhD, Max Qian, Syed Rizvi, Anjan Thakurta, PhD, Nizar J. Bahlis, MD
Journal: Blood
Blood (2016) 128 (22): 4497.
https://doi.org/10.1182/blood.V128.22.4497.4497
Published: 2016
Journal Articles

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

Clinical Trials & Observations
James R. Berenson, Alan Cartmell, Alberto Bessudo, Roger M. Lyons, Wael Harb, Dimitrios Tzachanis, Richy Agajanian, Ralph Boccia, Morton Coleman, Robert A. Moss, Robert M. Rifkin, Priti Patel, Sandra Dixon, Ying Ou, Janet Anderl, Sanjay Aggarwal, Jesus G. Berdeja
Journal: Blood
Blood (2016) 127 (26): 3360–3368.
https://doi.org/10.1182/blood-2015-11-683854
Published: 2016
Includes: Supplemental data
Journal Articles

Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Updated Results from the Phase 1/2 Study Champion-1 (NCT01677858)

James Berenson, MD, Alan Cartmell, Roger Lyons, Wael Harb, Dimitrios Tzachanis, Richy Agajanian, Ralph V. Boccia, MD, Morton Coleman, Robert A. Moss, MD, Robert M. Rifkin, Marco Schupp, Sandra Dixon, Ying Ou, Janet Anderl, Jesus G. Berdeja, MD
Journal: Blood
Blood (2015) 126 (23): 373.
https://doi.org/10.1182/blood.V126.23.373.373
Published: 2015
Journal Articles

Investigating Efficacy, Safety, and Biomarkers in a Phase 2 Trial of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Following Second-Line Lenalidomide-Based Therapy (Tx) in Relapsed or Refractory Multiple Myeloma (RRMM)

David S Siegel, Gary Schiller, Kevin Song, Richy Agajanian, Keith Stockerl-Goldstein, Hakan Kaya, Michael Sebag, Frederic J Reu, Jorge Mouro, Michael Sturniolo, Shankar Srinivasan, Anjan Thakurta, Yasir Nagarwala, Nizar J Bahlis, MD
Journal: Blood
Blood (2015) 126 (23): 1853.
https://doi.org/10.1182/blood.V126.23.1853.1853
Published: 2015